Glen Eagle Advisors, LLC Esperion Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 13, 2024	SELL	$4.81 - $11.92 $529 - $1,311	-110 Closed	0 $0
Q1 2021 Aug 13, 2024	SELL	$25.12 - $36.89 $3,893 - $5,717	-155 Reduced 58.49%	110 $3.09 Million
Q4 2020 Aug 13, 2024	BUY	$24.2 - $35.76 $6,413 - $9,476	265 New	265 $6.89 Million
Q3 2020 Aug 13, 2024	BUY	$31.18 - $52.71 $623 - $1,054	20 Added 12.5%	180 $6.69 Million
Q1 2020 Aug 13, 2024	BUY	$27.44 - $73.84 $823 - $2,215	30 Added 23.08%	160 $5.05 Million
Q2 2019 Aug 13, 2024	BUY	$40.1 - $52.33 $2,005 - $2,616	50 Added 62.5%	130 $6.05 Million
Q1 2019 Aug 13, 2024	BUY	$40.11 - $53.57 $3,208 - $4,285	80 New	80 $3.21 Million

200

116M

479K

700K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $193M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.